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Objective: In this article, we present two case reports.The first case was a malignant germ
cell tumor of the right ovary in a 23-year old woman and the second case was a bilateral
undifferentiated granulosa cell tumor in a 71-year old woman.The aim of these reports is to
illustrate the interest of the immunohistochemical analysis to define the correct diagnosis,
to better classify these ovarian tumors and improve their management.
Methods: In this study, we report two cases.The first case concerns a 23-year old woman
(A) with a mixed germ cell tumor of the right ovary [dysgerminoma (75%), yolk sac tumor
(20%), and a mature teratoma (5%)], and the second case concerns a 71-year old woman
(B) with a bilateral non-differentiated and necrotic granulosa cell tumor of both ovaries.The
staging system was used according to both the classifications: International Federation of
Gynaecology and Obstetrics 1987 for ovarian cancer and TNM code 2009.
Results: The immunostaining establishes the malignancy and the immunochemistry
contributes to confirm effectively the right diagnosis (Tables 2 and 3).
Conclusion: An immunohistochemical analysis is mandatory for the choice of chemother-
apy to obtain a better response of the disease and improve the survival prognosis. The
efficiency of the chemotherapy authorizes a conservative surgery including a unilateral
salpingo-oophorectomy preserving fertility (A). Concerning the non-dysgerminoma tumor
(B), and after a surgical staging and debulking, chemotherapy was recommended.The type
of tumor and its histological feature conditioned the choice of treatment.The benefit of the
immunohistological analysis in this case allowed the right adjuvant treatment.
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INTRODUCTION
Malignant ovarian germ cell tumors (OGCTs) comprise only 2–
5% of all ovarian cancers. They are different significantly from
epithelial ovarian cancers. They are concerned with women at
the childbearing age and a better prognosis when compared
with epithelial counterparts. Moreover, these patients will retain
their fertility after multimodal treatment. It is the reason why
an accurate diagnosis, staging, and treatment must be realized
early to improve the prognosis, the results, and their fertility
future.
The treatment outcomes also depend on the stage of disease at
the moment of diagnosis. Chemosensitivity is also dependent on
the types of OGCT and differing prognoses.
EPIDEMIOLOGY
Ovarian germ cell tumors are very rare ovarian tumors, up to 5%
of malignancies and exceptional over the age of 40 years. Before
the menarche and between 13 and 20 years, 90% of ovarian tumors
are OGCTs, 60% of them are of germ cell origin, with 65% being
malignant (1). It is very difficult to define associated etiological fac-
tors (2). But according to Teter and Boczkowski (3), it seems that
the presence of dysgenic ovaries is a predisposing factor to dysger-
minoma development. Mandel et al. described familial cases (4).
A Norwegian prospective study in 1997 showed some evidence
that pregnancy is sometimes associated with an increased risk of
developing an OGCT (5).
PATHOLOGY
In the embryo, germ cells appear in the wall of the yolk sac,
and then migrate to the genital ridge. They incorporate into
the developing gonad. OGCT are derived from the differenti-
ation of these germ cells into somatic tissues (teratoma), ger-
minal epithelium (dysgerminoma), extra-embryonic trophoblast
(choriocarcinoma), and yolk sac (yolk sac tumor) (2).
According to WHO, germ cell tumors are classified as dys-
germinomas or non-dysgerminomas. Dysgerminomas are the
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most common (50%) and considered to be the female equivalent
of testicular seminomas. However, mixed component germ cell
tumors accounted for 10% of all germ tumors.
In case of non-dysgerminomas, these tumors are known to
form embryonic or extra-embryonic histological patterns. Yolk
sac tumors and embryonic carcinoma (endodermal sinus tumors)
are highly malignant and represent 20% of OGCTs (2). The bilat-
eralism of these tumors is rare, and they grow rapidly in the intra-
peritoneal space secreting AFP. It is usual that non-dysgerminomas
were found to be associated with immature teratoma that con-
tains components derived from all three primitive germ layers.
The identification of more than one element in the tumor implies
treatment modification (2). Lastly, other tumors like embryonic
carcinoma, choriocarcinoma, and polyembryoma are classified as
non-dysgerminomas.
The benefit of immunohistochemistry (IHC) was shown to be
evidence-based. All these tumors were known to produce serum
markers that are useful for pre-operative workup, diagnosis, and
monitoring of both disease progression and response to treat-
ment (6). AFP and β-hCG are produced in some of the germ cell
tumors. Dysgerminomas produce commonly lactate dehydroge-
nase (LDH) and also sometimes HCG. When present, this marker
suggests a mixed germ cell tumor.
MATERIALS AND METHODS
This study includes a report of two cases.
PRESENTING SIGNS AND SYMPTOMS
The first case concerned a 23-year old young woman (A) with a
mixed germ cell tumor of right ovary. The tumor was composed
of 75% dysgerminoma, 20% yolk sac tumor, and 5% mature ter-
atoma. This patient was virgo and desires a future pregnancy with
an impact on her management. She was admitted in an emergency
with the most frequent primary symptoms: abdominal pain, an
enormous palpable pelvic mass on examination, and an abdominal
distension. The duration of symptoms ranged from 3 months.
The second case (B) was a 71-year old woman with a bilateral
non-differentiated and necrotic granulosa cell tumor. A previous
total hysterectomy with bilateral adnexectomy was performed a
few years ago for a benign tumor. She has presented the same
symptoms associated with 1-year history of abdominal disten-
sion for the second nausea and vomiting, urinary symptoms with
bilateral kidney dilatation, and hypertension. The co morbidities
were obesity, cardiac disease (left ventricular insufficiency), kid-
ney insufficiency, and bilateral pleural effusion. These symptoms
occurred since 11 years.
In the two cases, the staging system was used according to
the classification of International Federation of Gynaecology and
Obstetrics (FIGO) 1987 for ovarian cancer and TNM code 2009.
The clinical picture depends on the rapidity of tumor growth.
If dysgerminomas are growing slower, they may present with
non-specific abdominal symptoms (2).
RESULTS
DIAGNOSTIC IMAGING
Abdominal ultrasound was the first and most common investiga-
tion performed in these two patients.
The first patient (A) presented a bilateral kidney dilatation,
probably due to a mechanical and external compressive process.
The size of right ovary was 16 cm in diameter with a normal left
ovary and without ascites.
An abdominal magnetic resonance imaging was performed
showing a pelvic mass of 16 cm diameter, an important thick-
ness (solid aspect), with a second central tumor inside with a
hemorrhagic portion.
Concerning the second patient (B), ultrasounds and CT scan
showed a very voluminous intra abdominal mass with ascites, peri-
toneal and omentum metastasis nodules, and a bilateral kidney
dilatation during the urinary time. Ultrasound imaging showed
an irregular thickness on the bladder wall, a heterogeneous and
flaking aspect of the abdominal mass with hyper vascular signs on
Doppler.
TUMOR MARKERS
In the pre-operative workup, the dosages of serum markers AFP,
HCG, AMH, beta HCG, and LDH are useful because the germ
cell tumors are produced by them. These tumor markers have
a role in diagnosis, monitoring progression, and response to
treatment.
Dysgerminomas produce LDH and sometimes HCG. In this
case, HCG suggests the presence of a mixed germ cell that
the tumor contains. A choriocarcinoma can produce HCG and
endodermal sinus tumors AFP.
Finally, depending on their composition, the germ cell tumor
can be associated with elevation of either or both tumor mark-
ers (6–8).
The first patient (A) had AMH (7–9 pmol/l), LDH ele-
vated (3861 UI/l), beta HCG (118 UI/l), CA-125 (136 UI/ml), E2
(310 pmol/l), and AFP (50 ng/ml). The tumor corresponded to a
germ cell tumor (dysgerminoma 75%, yolk sac tumor 25%, and
teratoma 5%).
The second patient (B) had CA-125 (266 UI/ml), CA-
19.9 (7 UI/ml), CEA (6.2 ng/ml), CA-15.3 (18.4 UI/ml), LDH
(1.17 UI/ml), and HCG (2.5 UI/ml).
SURGICAL MANAGEMENT
Surgery was the first treatment for these two patients. A fertility-
sparing operation was defined for the patient (A) as the preserva-
tion of the uterus and one ovary in order to maintain fertility (9).
Radical surgery included appendectomy for the patient (B).
The principles of cytoreductive surgery in ovarian cancer must
be applied to the management of OGCTs. But, for a young girl
desiring a pregnancy, the surgical treatment must be conservative,
without danger for the survival prognosis and preserve fertility.
In a series of 22 patients, Weinberg et al. (10) described 8 with
a spontaneous pregnancy for a fertility rate of 80%, resulting in 11
live full-term births.
The potential after fertility-sparing surgery and post-operative
chemotherapy is excellent.
There is a general consensus for a midline incision, unilateral
salpingo-oophorectomy, and a complete staging of the peritoneal
cavity, with an appendicectomy and omentectomy.
At the beginning of the surgical process, cytology must be per-
formed, with biopsies of any suspicious areas in the peritoneum.
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A bulky residual disease reduces the effect of chemotherapy and
the survival (11). At last, the largest study addressing the issue of
routine lymph node sampling did not produce clear evidence that
this was advantageous (12).
Bailey and Church (2) state that the extent of surgical resection
requires careful judgment and knows that the debulking procedure
must be achieved with acceptable surgical morbidity allowing the
excellent impact of chemotherapy in OGCTs.
• The young patient (A) was operated by an esthetic Pfannenstiel
incision, and a midline incision under the skin to obtain a large
space for removing the mass without rupture.
The technique consists to exteriorize the tumor outside from
the peritoneal cavity, allowing the right salpingo-oophorectomy,
the ligature of vascular pedicles. The pathologist is in the operating
theater. Cytology was performed at first.
The tumor weight was 3700 g, 16 cm× 13 cm diameter, 11 cm
of thickness. The capsule is smooth and shining, white color
with a cerebral aspect, without rupture visible macroscopically
(Figure 1). After cutting into two parts, a yellow tumor appeared
with a hemorrhagic and necrotic center nearing the ovarian hilum
(Figure 1).
Many peritoneal biopsies were performed beside right and left
bowels, inside the cul-de-sac of Douglas, under the diaphragm and
partial omentectomy. The left ovary was normal.
• The second patient (B) 71 years old presented on emergencies
an enormous abdominal mass with a sub occlusion and many co
FIGURE 1 | Macroscopic view of germ cell tumor.
morbidities: a chronic ischemic heart disease (FEVG 30%), acute
renal failure multifactorial with a bilateral ureteral compression
by the pelvic mass, iron deficiency anemia, and a respiratory
failure with pleural effusion.
The pose by cystoscopy and UPR of pre-operative probes (dou-
ble J) has facilitated ureteral diuresis (no suspicious lesions endo
vesical).
A midline above and below the umbilicus allowed access to
the peritoneal cavity and the discovery of a voluminous tumor
(>13 cm diameter), intra-peritoneal bleedings (300 cc), and bowel
adhesions. The tumor compressed the rectum and the bowel
sigmoid.
Seen that the patient have had a previous surgery (total hys-
terectomy and bilateral adnexectomy), the origin seemed to be
from the retro peritoneum or ovarian remnants.
A metastasis is discovered on the root of mesentery, 3 cm diam-
eter at the departure of inferior mesentery artery. A biopsy is
realized.
The tumor (Figure 2) is removed with an appendectomy but
the bleedings obliged to let inside a packing to perform hemostasis.
An embolization was realized at the same time.
A reoperation was performed 24 h later to remove the packing.
HISTOLOGY
The interest of these reports is to understand the difficulties to
have an optimal diagnosis to perform the management.
The risk of malignancies is between 20 and 55% reported in
previous studies (13).
FIGURE 2 | Macroscopic view of granulosa tumor.
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If the diagnosis is not possible macroscopically, the microscopic
examination is always useful. Helped by reasoning on immuno-
chemistry identification, diagnosis is obtained by elimination.
• The case (A) is concerning a 16 cm× 13 cm long left ovary
(Figure 1). The intraoperative frozen section showed a dys-
germinoma. The immunochemistry helped to refine the diag-
nosis (Table 1), and confirmed the germ cell tumor with
the percentage of dysgerminoma, yolk sac tumor, and mature
teratoma.
• For the patient (B), the first cytological and morphologic
aspect evoked a tumor of sex cord stromal ovarian origin.
But the arrangement vascular evoked also a neuro endocrinal
tumor (PNET: neuro ectodermal primitive tumor) and the
morphologic aspect a synovial sarcoma.
The others possible diagnosis could have been an endometrial
sarcoma, and with the histo morphological aspect a malignant
adrenal tumor, finally a small cell carcinoma hypercalcemic type.
In this case, the immunostaining (NSE) confirms the malig-
nancy and the immunochemistry allows the reasoning to deter-
mine effectively the right diagnosis (Tables 2 and 3).
The final diagnosis is a granulosa tumor of ovary with 40% of
necrosis.
IMMUNOCHEMISTRY
Immunohistochemistry is a wide-used biological technique that
combines anatomy, physiology, immunology, and biochem-
istry (14–16).
The procedure is using the antigen–antibody binding reaction
and in this case the IHC can be considered as a method that visu-
alizes distribution and localization of specific antigen or cellular
components in separated tissues or tissue sections (14). Compared
to other bio-techniques using antigen–antibody reactions such
as immuno-precipitation, or western-blot, IHC provides in situ
information, which promises a more efficient experimental result.
These techniques require at least three sequences:
(1) a primary antibody, which is binding to specific antigen;
(2) the antibody–antigen complex formed by incubation with a
secondary enzyme-conjugated antibody;
(3) then, the enzyme in the presence of substrate and chro-
mogen catalyzes to generate colored deposits at the sites of
antibody–antigen binding.
The results are detailed for each case in Table 1 for the case (A)
and Tables 2 and 3 for the case (B).
DISCUSSION
In view of the high risk of malignancy, ovarian masses should be
managed as though they were malignant until proven otherwise.
But, often, the diagnosis of malignancy is not obvious, following
the tumor nature.
The results about these two cases are demonstrative and illus-
trate the difficulties to obtain the correct diagnosis. The following
management and consequently the prognosis depend on it. The
prognosis of OGCT has improved vastly over the last 30 years due
to modern chemotherapy (2).
Table 1 | Markers of germ cell tumor (A).
Markers Dysgerminoma
seminoma 75%
Yolk sac
tumor 25%
Mature
teratoma 5%
Cytokeratines AE1/AE3 − +
PLAP + −
CD 117 + 25% +
CD 30 10% + −
EMA 30% + 5% +
CA-19.9 10% + 20% +
Vimentin (stroma) 100% + 100% +
CA-125 20% + 10% +
CD 10 − −
CK 7 − 20% +
Table 2 | Negative markers of tumor (B).
Synaptophysine chromogranine − Eliminate endocrine tumors
Cytokeratines 20/7 −
TTF1 − Eliminate lung tumors
Melan-A HMB 45 − Eliminate adrenocortical tumors
Cytokeratines AE1/AE3 −
CD45 LCA − Eliminate lymphomas
Cytokeratines 8/9 CD 10 −
CA-125 −
WT1 −
Table 3 | Positive markers of tumor (B).
Calretinin vimentin
inhibin CD 99
80% + In according with a granulosa
tumor of ovary
SMA BCL2 50% + In according with a granulosa
tumor of ovary
The reason why a correct immunohistochemical examination
is necessary explains the choice of chemotherapy used to obtain
the best response and improve the prognosis of survival. The effi-
cacy of chemotherapy now allows conservative surgery including
only a unilateral salpingo-oophorectomy preserving fertility (A).
Krishnansu Tewari reports that the evolution of systemic treat-
ment for ovarian germ cell cancer (A) has paralleled the advances
made in the treatment of testicular germ cell cancers because of
the biologic similarity between ovarian and testicular germ cell
tumors (17, 18). Furthermore, all data confirmed that with an
effective adjuvant therapy (chemotherapy) (19) and a conserv-
ative surgery, most women with ovarian germ cell malignancies
have a good survival rate of 93%. They will be able to retain their
menstrual and reproductive potential after treatment (17).
Concerning other non-dysgerminoma tumors (B), after a
surgical staging and treatment, chemotherapy is delivered in
front-line (BEP: cysplatin, etoposide, bleomycin). The choice of
treatment is conditioned by the type of tumor and its histological
feature.
In case of this patient (B), the immuno-histological reasoning
allowed the right adjuvant post-operative treatment (10).
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Journal/10.3389/fonc.2014.
00097/abstract
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